Species |
Human |
Protein Construction |
Avi |
His |
EGFRVIII (Leu25-Ser378) Accession # NP_001333870.1 |
N-term |
|
C-term |
|
Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Immobilized EGFRVIII, His&Avi, Human (Cat.No.: Z03940) at 1 μg/ml (100μl/Well) on the plate can bind Anti-EGFRVIII Antibody, hFc Tag. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
41.6 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 68-80 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |

Immobilized EGFRVIII, His & Avi, Human at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-EGFRVIII Antibody, hFc Tag with the EC50 of 9.2 ng/ml determined by ELISA.

EGFRVIII, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

The purity of EGFRVIII, His & Avi, Human is greater than 95% as determined by SEC-HPLC.
Target Background |
Epidermal growth factor receptor (EGFR) is a transmembrane protein. It can be activated by epidermal growth factor or transforming growth factor alpha (TGF-α). EGFR plays an important role in cell survival, proliferation and angiogenesis. EGFR is highly expressed in a variety of solid tumours. It is a common target for cancer therapy. |
Synonyms |
ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.